PerkinElmer. with ticker code (PKI) now have 15 market analysts covering the stock. The analyst consensus now points to a rating of ‘Buy’. The target price High/Low ranges between 185 and 134 with the average target price sitting at $158.06. Given that the stocks previous close was at $135.48 this would indicate that there is a potential upside of 16.7%. The 50 day MA is $129.80 and the 200 day MA is $135.61. The company has a market cap of $16,743m. Visit the company website at: https://www.perkinelmer.com
The potential market cap would be $19,534m based on the market consensus.
PerkinElmer. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspectsluding air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseasesluding down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer. was founded in 1937 and is headquartered in Waltham, Massachusetts.
The company has a dividend yield of 0.21% with the ex dividend date set at 20-4-2023 (DMY).
Other points of data to note are a P/E ratio of 32.54, revenue per share of 26.25 and a 3.69% return on assets.
